N-(1-(3-ethoxybenzyl)piperidin-3-yl)-1H-indazol-5-amine | 1035095-45-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: N-(1-(3-ethoxybenzyl)piperidin-3-yl)-1H-indazol-5-amine
• 英文别名: N-[1-(3-Ethoxybenzyl)piperidin-3-yl]-1H-indazol-5-amine；N-[1-[(3-ethoxyphenyl)methyl]piperidin-3-yl]-1H-indazol-5-amine
• CAS: 1035095-45-4
• 化学式: C₂₁H₂₆N₄O
• 分子量: 350.464
• InChiKey: SXUKHUQRLXBBJH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  53.2
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE
  申请人：Lampe John W.

  公开号：US20080214614A1

  公开（公告）日：2008-09-04

  The present invention is directed to synthetic cytoskeletal active compounds that are inhibitors of rho-associated protein kinase. The present invention is also directed to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier. The invention is additionally directed to a method of preventing or treating diseases or conditions associated with cytoskeletal reorganization. In one embodiment of the invention, the method treats increased intraocular pressure, such as primary open-angle glaucoma. The method comprises administering to a subject a therapeutically effective amount of a cytoskeletal active compound of Formula I or Formula II, wherein said amount is effective to influence the actomyosin interactions, for example by leading to cellular relaxation and alterations in cell-substratum adhesions.

  本发明涉及一种合成的细胞骨架活性化合物，其为rho相关蛋白激酶的抑制剂。本发明还涉及包含此类化合物和药用载体的制药组合物。此外，本发明还涉及一种预防或治疗与细胞骨架重组相关的疾病或病症的方法。在本发明的一个实施例中，该方法治疗增加的眼内压，如原发性开角型青光眼。该方法包括向受体施用公式I或公式II的细胞骨架活性化合物的治疗有效量，其中该量能够影响肌动蛋白相互作用，例如通过导致细胞松弛和细胞基质附着的改变。
• Method for treating gout and binding uric acid
  申请人：GelTex Pharmaceutical, Inc.

  公开号：US20030039627A1

  公开（公告）日：2003-02-27

  A method for treating gout and/or reducing serum uric acid levels in a patient is disclosed that includes administering to the patient a therapeutically effective amount of an amine polymer, for example, an aliphatic amine polymer. In one embodiment, the polymer binds to uric acid or a precursor thereof. Examples of polymers useful in an embodiment of the invention include sevelamer hydrochloride and colesevelam. The invention includes the use of amine polymers such as a cross-linked polymer characterized by a repeat unit having the formula: 1 and salts and copolymers thereof, where n is a positive integer and x is zero or an integer between 1 and about 4. Also described is a use, for the manufacture of a medicament, of a polymer that binds serum uric acid in a patient.

  本发明揭示了一种治疗痛风和/或减少患者血清尿酸水平的方法，包括向患者投予治疗有效量的胺基高分子，例如脂肪族胺基高分子。在一种实施例中，该高分子与尿酸或其前体结合。在本发明实施例中有用的高分子的例子包括盐酸西维拉麦和考来西韦。本发明包括使用胺基高分子，例如交联聚合物，其重复单元具有公式1，以及其盐和共聚物，其中n是正整数，x为0或介于1到约4之间的整数。本发明还描述了一种用于制造药物的用途，该药物能够结合患者血清尿酸。
• Method for lowering serum glucose
  申请人：Burke K. Steven

  公开号：US20070286841A1

  公开（公告）日：2007-12-13

  A method for treating hyperglycemia and/or reducing serum glucose levels in a patient that includes administering to the patient a therapeutically effective amount of an amine polymer is disclosed. In one embodiment, the amine polymer is aliphatic. Examples of polymers useful in an embodiment of the invention include sevelamer hydrogen chloride and colesevelam. The invention includes the use of amine polymers such as a cross-linked polymer characterized by a repeat unit having the formula: and salts and copolymers thereof, where n is a positive integer and x is zero or an integer between 1 and about 4. Also described is a use, for the manufacture of a medicament, of a polymer that lowers serum glucose.

  本发明公开了一种治疗高血糖和/或降低患者血清葡萄糖水平的方法，包括向患者投予治疗有效量的胺基聚合物。在一种实施例中，该胺基聚合物是脂肪族的。本发明的实施例中有用的聚合物的例子包括盐酸西维拉麦和考来西酰胺。本发明包括使用胺基聚合物，例如交联聚合物，其特征在于重复单元具有以下公式：及其盐和共聚物，其中n是正整数，x为零或介于1和约4之间的整数。本发明还描述了一种用于制造药物的聚合物，其降低血清葡萄糖。
• Use of aliphatic polyamines for reducing oxalate
  申请人：GENZYME CORPORATION

  公开号：EP1645278A2

  公开（公告）日：2006-04-12

  A method for reducing oxalate levels in a patient that includes administering to the patient a therapeutically effective amount of non-ahsorbable amine polymers such as a polymer characterized by a repeat unit having formula (1) and salts and copolymers thereof, where n is a positive integer and x is zero or an integer between 1 and about 4.

  一种降低患者体内草酸盐含量的方法，包括向患者施用治疗有效量的非吸收性胺聚合物，例如由具有式（1）的重复单元表征的聚合物及其盐类和共聚物，其中 n 为正整数，x 为零或 1 至约 4 之间的整数。
• Method for reducing oxalate
  申请人：GelTex Pharmaceutical, Inc.

  公开号：US20010051660A1

  公开（公告）日：2001-12-13

  A method for reducing oxalate levels in a patient that includes administering to the patient a therapeutically effective amount of non-absorbable amine polymers such as a polymer characterized by a repeat unit having the formula: 1 and salts and copolymers thereof, where n is a positive integer and x is zero or an integer between 1 and about 4.

  一种降低患者体内草酸盐水平的方法，包括向患者施用治疗有效量的非吸收性胺聚合物，如一种聚合物，其特征在于具有如下式的重复单元： 1 及其盐和共聚物，其中 n 为正整数，x 为零或 1 至约 4 之间的整数。